TheraRadar
← Back
Data updated: Mar 29, 2026

SHILPA

OncologyGastroenterology
Generics

SHILPA is a generic drug manufacturer focused on Oncology, Gastroenterology. Key products include PEMETREXED.

2015
Since
12
Drugs
-
Trials
99
Approved (2yr)

Key Drugs

PEMETREXED
pemetrexed disodium
Oncology
Dihydrofolate Reductase 2 indications · 2020

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ZOLEDRONIC ACID 2026-02-05
CAPECITABINE 2026-01-27
Labeling
VARENICLINE TARTRATE 2026-01-09
BORTEZOMIB 2026-01-06
VARENICLINE TARTRATE 2025-12-18
Labeling
BORTEZOMIB 2025-12-17
VARENICLINE TARTRATE 2025-10-29
VARENICLINE TARTRATE 2025-09-24
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 80%
4 drugs
Gastroenterology 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Oncology, Gastroenterology
Gilead Sciences biotech
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology